Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.
The journey to a dream job isn’t always straight. This video recommends what to do when life gets in the way of your career or your needs or preferences change.
Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Oncology is a fast-moving, challenging and complex field and only with collaboration between different disciplines, we can be able to win the fight against cancer.